Samsung Biologics

Research evidence excerpt

Samsung Biologics

liability company under German law registered in the Commercial Register

of the Court of Frankfurt/Main under HRB 110223. NFPE is authorized and regulated by the German Federal Financial Supervisory Authority

(BaFin).

This document has been approved by NIHK, which is regulated by the Hong Kong Securities and Futures Commission, for distribution in Hong

Kong by NIHK. This document is intended only for investors who are 'professional investors' for the purposes of applicable regulations in Hong

Kong and may not, therefore, be redistributed to persons who are not 'professional investors' for such purposes.

This document has been approved for distribution in Australia by NAL, which is authorized and regulated in Australia by the ASIC.

This document has also been approved for distribution in Malaysia by NSM.

In Singapore, this document has been distributed by NSL, an exempt financial adviser as defined under the Financial Advisers Act (Chapter

110), among other things, and regulated by the Monetary Authority of Singapore. NSL may distribute this document produced by its foreign

affiliates pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. This document is intended for accredited,

expert or institutional investors as defined by the Securities and Futures Act (Chapter 289). Where the recipient of this document is not an

accredited, expert or institutional investor, NSL accepts legal responsibility for the contents of this document in respect of such recipient only to

the extent required by law. Recipients of this document in Singapore should contact NSL in respect of matters arising from, or in connection

with, this document. THIS DOCUMENT IS INTENDED FOR GENERAL CIRCULATION. IT DOES NOT TAKE INTO ACCOUNT THE SPECIFIC